At the 18-month follow-up , moderate vision loss ( loss of 3 lines or more of best-corrected visual acuity [ BCVA ] ) and severe vision loss ( BCVA < 5/200 Snellen ) occurred significantly less frequently in the triamcinolone group than in the control group ( 31 % vs. 48 % [ P = 0.039 ] and 5 % vs. 15 % [ P = 0.048 ] , respectively ) .
